OncoTherapy Science (TSE:4564) Beneish M-Score: -3.41 (As of Jul. 08, 2026)


TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円21.00
GF Value 円17.03
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Beneish M-Score?

OncoTherapy Science TSE:4564 +5.00% 50 Beneish M-Score is -3.41 as of Jul. 08, 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.03 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 824 Biotechnology companies, OncoTherapy Science ranks better than 82.16% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.41 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for OncoTherapy Science's Beneish M-Score or its related term are showing as below:

TSE:4564' s Beneish M-Score Range Over the Past 10 Years
Min: -5.46   Med: -2.41   Max: 22.83
Current: -3.41

During the past 13 years, the highest Beneish M-Score of OncoTherapy Science was 22.83. The lowest was -5.46. And the median was -2.41.


OncoTherapy Science Beneish M-Score Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Beneish M-Score Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.37 -3.14 -4.28 7.41 -3.41

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.28 0.00 7.41 0.00 -3.41

TSE:4564 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, OncoTherapy Science's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Beneish M-Score falls into.


TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of OncoTherapy Science for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9717+0.528 * -0.9847+0.404 * 0.4896+0.892 * 1.078+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.913+4.679 * 0.005134-0.327 * 0.2539
=-3.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円103.5 Mil.
Revenue was 円808.5 Mil.
Gross Profit was 円14.0 Mil.
Total Current Assets was 円2,309.8 Mil.
Total Assets was 円2,359.4 Mil.
Property, Plant and Equipment(Net PPE) was 円0.0 Mil.
Depreciation, Depletion and Amortization(DDA) was 円0.0 Mil.
Selling, General, & Admin. Expense(SGA) was 円289.4 Mil.
Total Current Liabilities was 円170.0 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.0 Mil.
Net Income was 円-910.6 Mil.
Gross Profit was 円0.0 Mil.
Cash Flow from Operations was 円-922.8 Mil.
Total Receivables was 円98.9 Mil.
Revenue was 円750.0 Mil.
Gross Profit was 円-12.8 Mil.
Total Current Assets was 円1,105.7 Mil.
Total Assets was 円1,155.2 Mil.
Property, Plant and Equipment(Net PPE) was 円0.0 Mil.
Depreciation, Depletion and Amortization(DDA) was 円0.0 Mil.
Selling, General, & Admin. Expense(SGA) was 円294.1 Mil.
Total Current Liabilities was 円327.7 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(103.542 / 808.53) / (98.855 / 750.048)
=0.128062 / 0.131798
=0.9717

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-12.756 / 750.048) / (13.965 / 808.53)
=-0.017007 / 0.017272
=-0.9847

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2309.848 + 0) / 2359.354) / (1 - (1105.697 + 0) / 1155.203)
=0.020983 / 0.042855
=0.4896

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=808.53 / 750.048
=1.078

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 0)) / (0 / (0 + 0))
= /
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(289.409 / 808.53) / (294.067 / 750.048)
=0.357945 / 0.392064
=0.913

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 169.967) / 2359.354) / ((0 + 327.738) / 1155.203)
=0.07204 / 0.283706
=0.2539

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-910.638 - 0 - -922.751) / 2359.354
=0.005134

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

OncoTherapy Science has a M-score of -3.41 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.41 mean?
OncoTherapy Science (TSE:4564) has a Beneish M-Score of -3.41 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #147 out of 824 companies in the Biotechnology industry, placing it in the top 17.8%.
Is OncoTherapy Science's Beneish M-Score too high?
OncoTherapy Science's current Beneish M-Score is -3.41. Based on the distribution chart, OncoTherapy Science ranks #147 out of 824 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #147 out of 824 companies for Beneish M-Score. This places OncoTherapy Science in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Beneish M-Score is -3.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.03, compared to a current price of 円21.00 — trading 23.3% above its estimated fair value. The current Beneish M-Score is -3.41. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Beneish M-Score is -3.41 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 23.3% above its estimated GF Value™ of 円17.03. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • Beneish M-Score: -3.41
  • GF Value™: 円17.03 vs. price of 円21.00 (23.3% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円17.03
GF Value